Targeting the human epidermal growth factor receptor 2 in esophageal cancer

Cancer Control

Volumn 20, Issue 2, 2013, Pages 111-116

  Almhanna, Khaldoun ^a   Meredith, Kenneth L ^a   Hoffe, Sarah E ^a   Shridhar, Ravi ^a   Coppola, Domenico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION CANCER; GASTROESOPHAGEAL JUNCTION TUMOR; HUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH TUMOR; TREATMENT OUTCOME;

EID: 84875835009     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000204     Document Type: Article

References (28)

1. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468-1470.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
4. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21(10): 1999-2004.
5. Ohtsu A, Shah MA, VanCutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968-3976.
6. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB- related gene in a human mammary carcinoma. Science. 1985;229(4717): 974-976.
7. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385-389.
8. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-1139.
9. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986;1(8484):765-767.
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-712.
11. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunore- activity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51(3):1034-1038.
12. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743. Erratum in: N Engl J Med. 2007;356(14):1487.
13. Yoon HH, Shi Q, Sukov WR, et al. HER2 expression/amplification: frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2011;29(suppl):4012.
14. Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). J Clin Oncol (ASCO Annual Meeting Abstracts). 2011;29(suppl):4046.
15. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273-278.
16. Gravalos C, Márquez A, García-Carbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. 2007 Gastrointestinal Symposium. 2007;89.
17. Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer. 2007;5(4):271. Abstract 3541.
18. Bilous M, Osamura RY, Rüschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2010;41(2):304-305; author reply: 305-306.
19. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40(6):769-777.
20. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104(9):1372-1376.
21. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
22. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohisto- chemical testing. Virchows Arch. 2010;457(3):299-307.
23. Nicholas G, Cripps C, Au H-J, et al. Early results of a trial of trastu- zumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer over-expressing HER2. Ann Oncol. 2006;17(suppl 9):316. Abstract 1105P.
24. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/ neu overexpression/amplification. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25:4613.
25. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
26. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3): 533-543.
27. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011;22(12):2610-2615.
28. Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. 2008 Gastrointestinal Cancers Symposium. Abstract 43.